Patients with moderate to severe ileocolonic Crohn's disease (CD) who received adalimumab induction and maintenance therapy had greater rates of mucosal healing than patients who received placebo after adalimumab induction therapy in a 52-week trial (EXTend the Safety and Efficacy of Adalimumab Through ENDoscopic Healing).
Dr Jean–Frédéric Colombel and colleagues from New York, USA investigated whether this treatment also induced deep remission—a composite clinical and endoscopic end point.
Rates of deep remission, defined as the absence of mucosal ulceration and Crohn's disease Activity Index scores less than 150, were compared between patients given continuous adalimumab and those given only induction therapy followed by placebo.
The team assessed the relationships between deep remission and other outcomes among patients who received adalimumab.
|Rates of deep remission were greatest among patients who received adalimumab|
|Clinical Gastroenterology & Hepatology|
The outcomes of patients with deep remission were compared with those of patients with only the absence of mucosal ulceration or only clinical remission.
Rates of deep remission were 16% in patients given adalimumab vs 10% in those given placebo at week 12, and 19% vs 0% at week 52.
The research team found that rates of deep remission were greatest among patients who received adalimumab and had Crohn's disease for 2 years or less.
At week 52, patients who achieved deep remission at week 12 required significantly fewer adalimumab treatment adjustments, hospitalizations, and Crohn's disease-related surgeries.
The patients also had significantly less activity impairment, and had better quality of life and physical function compared with patients not achieving deep remission.
Deep remission generally was associated with better outcomes than only an absence of mucosal ulceration, outcomes of patients with deep remission vs only clinical remission were similar.
The team noted that deep remission was associated with estimated total cost savings of $10,360 compared with lack of deep remission.
Dr Colombel's team concludes, "In an exploratory study of patients with moderate to severe ileocolonic Crohn's disease who received adalimumab induction and maintenance therapy, patients achieving deep remission appeared to have better 1-year outcomes than those not achieving deep remission."
"These findings should be validated in large, prospective trials."